Nuzenio

Fda Approves Lutetium

Fda Approves Lutetium news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 8 publisher sources 100/100 entity strength

Latest news

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT Dr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - OncLiveOncLive · Thu, 06 Aug 2026 16:51:58 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Mon, 03 Aug 2026 17:37:08 GMT Pluvicto Approved Earlier in Metastatic Prostate Cancer - MedscapeMedscape · Mon, 03 Aug 2026 14:03:57 GMT FDA approves expanded indication for Pluvicto - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 07:30:35 GMT FDA Approves Pluvicto for PSMA+ mAPMN/S Prostate Cancer - Oncology Nursing NewsOncology Nursing News · Sat, 01 Aug 2026 00:20:17 GMT FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 21:11:29 GMT FDA OKs Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 20:58:12 GMT

Timeline

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Thu, 06 Aug 2026 16:51:58 GMTDr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC - OncLive

Mon, 03 Aug 2026 17:37:08 GMTFDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care® (AJMC®)

Mon, 03 Aug 2026 14:03:57 GMTPluvicto Approved Earlier in Metastatic Prostate Cancer - Medscape

Mon, 03 Aug 2026 07:30:35 GMTFDA approves expanded indication for Pluvicto - The Pharma Letter

Sat, 01 Aug 2026 00:20:17 GMTFDA Approves Pluvicto for PSMA+ mAPMN/S Prostate Cancer - Oncology Nursing News

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

PSMA6 live mentions Vipivotide Tetraxetan4 live mentions Metastatic Prostate Cancer4 live mentions S Prostate Cancer4 live mentions FDA3 live mentions Pluvicto3 live mentions Lutetium Lu3 live mentions Earlier3 live mentions The American Journal3 live mentions Managed Care3 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Fda Approves Lutetium.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.